New circulating biomarkers for prostate cancer (Q36999680)

17 August 2017

1 reference

title

New circulating biomarkers for prostate cancer (English)

1 reference

17 August 2017

0 references

1 reference

Bensalah K

1 reference

17 August 2017

Lotan Y

series ordinal

1 reference

17 August 2017

Karam JA

series ordinal

1 reference

17 August 2017

Shariat SF

series ordinal

1 reference

17 August 2017

publication date

13 November 2007

1 reference

Prostate Cancer and Prostatic Diseases

17 August 2017

published in

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

112-120

1 reference

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

Interleukin-6 is an autocrine growth factor in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

The influence of finasteride on the development of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Most prostate cancers missed by raising the upper limit of normal prostate-specific antigen for men in their sixties are clinically significant.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Age-specific prostate-specific antigen: a reassessment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Measurement of complexed PSA improves specificity for early detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Complexed Prostate Specific Antigen Improves Specificity for Prostate Cancer Detection: Results of a Prospective Multicenter Clinical Trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Free prostate-specific antigen in serum is becoming more complex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Early identification of individuals with prostate cancer in negative biopsies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Detection of prostate cancer with a blood-based assay for early prostate cancer antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

EPCA-2: a highly specific serum marker for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Plasma Urokinase Receptor Levels in Patients With Colorectal Cancer: Relationship to Prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Association of transforming growth factor-β1 with prostate cancer: An immunohistochemical study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Transforming growth factor beta as a clinical biomarker for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Interleukin-6 in biology and medicine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Plasma chromogranin A in patients with prostate cancer improves the diagnostic efficacy of free/total prostate-specific antigen determination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Serum chromogranin-A in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Prostate-specific membrane antigen (PSMA): current benefits and future value

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Autoantibody signatures in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501026

7 January 2021

Identifiers

DOI

10.1038/SJ.PCAN.4501026

1 reference

17 August 2017

1 reference